Consideration of the Root Causes in Candidate Attrition During Oncology Drug Development

Clin Pharmacol Drug Dev. 2024 Sep;13(9):952-960. doi: 10.1002/cpdd.1464. Epub 2024 Aug 20.
No abstract available

Keywords: attrition reasons; cancer types; clinical phases; drug attrition; medication class; oncology drugs.

MeSH terms

  • Antineoplastic Agents* / administration & dosage
  • Antineoplastic Agents* / adverse effects
  • Drug Development*
  • Humans
  • Neoplasms / drug therapy

Substances

  • Antineoplastic Agents